RU2223116C2 - Применение производных арил (или гетероарил) азолилкарбинолов в приготовлении лекарственного средства для лечения нарушений, опосредованных избытком вещества p - Google Patents

Применение производных арил (или гетероарил) азолилкарбинолов в приготовлении лекарственного средства для лечения нарушений, опосредованных избытком вещества p Download PDF

Info

Publication number
RU2223116C2
RU2223116C2 RU2001106644/15A RU2001106644A RU2223116C2 RU 2223116 C2 RU2223116 C2 RU 2223116C2 RU 2001106644/15 A RU2001106644/15 A RU 2001106644/15A RU 2001106644 A RU2001106644 A RU 2001106644A RU 2223116 C2 RU2223116 C2 RU 2223116C2
Authority
RU
Russia
Prior art keywords
methyl
imidazole
dimethylamino
pyrazole
benzyl
Prior art date
Application number
RU2001106644/15A
Other languages
English (en)
Russian (ru)
Other versions
RU2001106644A (ru
Inventor
Рамон МЕРСЕ-ВИДАЛЬ (ES)
Рамон МЕРСЕ-ВИДАЛЬ
Хорди ФРИГОЛА-КОНСТАНСА (ES)
Хорди ФРИГОЛА-КОНСТАНСА
Original Assignee
Лабораторьос Дель Др. Эстев, С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Лабораторьос Дель Др. Эстев, С.А. filed Critical Лабораторьос Дель Др. Эстев, С.А.
Publication of RU2001106644A publication Critical patent/RU2001106644A/ru
Application granted granted Critical
Publication of RU2223116C2 publication Critical patent/RU2223116C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
RU2001106644/15A 1998-08-07 1999-08-05 Применение производных арил (или гетероарил) азолилкарбинолов в приготовлении лекарственного средства для лечения нарушений, опосредованных избытком вещества p RU2223116C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES009801708A ES2150378B1 (es) 1998-08-07 1998-08-07 Empleo de derivados de aril(o heteroaril)azolilcarbinoles en la elaboracion de un medicamento para el tratamiento de los trastornos mediados por un exceso de substancia p.
ESP9801708 1998-08-07

Publications (2)

Publication Number Publication Date
RU2001106644A RU2001106644A (ru) 2003-02-27
RU2223116C2 true RU2223116C2 (ru) 2004-02-10

Family

ID=8304839

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2001106644/15A RU2223116C2 (ru) 1998-08-07 1999-08-05 Применение производных арил (или гетероарил) азолилкарбинолов в приготовлении лекарственного средства для лечения нарушений, опосредованных избытком вещества p

Country Status (26)

Country Link
US (1) US6518295B1 (cg-RX-API-DMAC7.html)
EP (1) EP1103243B1 (cg-RX-API-DMAC7.html)
JP (1) JP2002522359A (cg-RX-API-DMAC7.html)
KR (1) KR100558506B1 (cg-RX-API-DMAC7.html)
CN (1) CN1151789C (cg-RX-API-DMAC7.html)
AR (1) AR019999A1 (cg-RX-API-DMAC7.html)
AT (1) ATE257379T1 (cg-RX-API-DMAC7.html)
AU (1) AU754124B2 (cg-RX-API-DMAC7.html)
BR (1) BR9912807A (cg-RX-API-DMAC7.html)
CA (1) CA2339661C (cg-RX-API-DMAC7.html)
CO (1) CO5080747A1 (cg-RX-API-DMAC7.html)
CZ (1) CZ292065B6 (cg-RX-API-DMAC7.html)
DE (1) DE69914085T8 (cg-RX-API-DMAC7.html)
DK (1) DK1103243T3 (cg-RX-API-DMAC7.html)
ES (2) ES2150378B1 (cg-RX-API-DMAC7.html)
HU (1) HUP0105428A3 (cg-RX-API-DMAC7.html)
IL (1) IL141295A0 (cg-RX-API-DMAC7.html)
NO (1) NO20010634L (cg-RX-API-DMAC7.html)
NZ (1) NZ509645A (cg-RX-API-DMAC7.html)
PL (1) PL193802B1 (cg-RX-API-DMAC7.html)
PT (1) PT1103243E (cg-RX-API-DMAC7.html)
RU (1) RU2223116C2 (cg-RX-API-DMAC7.html)
TR (1) TR200100378T2 (cg-RX-API-DMAC7.html)
TW (1) TW445259B (cg-RX-API-DMAC7.html)
WO (1) WO2000007542A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200100867B (cg-RX-API-DMAC7.html)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2174756B2 (es) * 2001-04-06 2003-11-16 Esteve Labor Dr Derivados de aril (o heteroaril) azolilcarbinoles para el tratamiento de enfermedades respiratorias.
ES2180449B1 (es) * 2001-07-06 2004-01-16 Esteve Labor Dr Derivados de aril (o heteroaril) azolilcarbinoles para el tratamiento de la incontinencia urinaria.
US20040142929A1 (en) * 2001-07-06 2004-07-22 Ramon Merce-Vidal Derivatives of aryl (or heteroaryl) azolylcarbinoles for the treatment of urinary incontinence
DE10335566A1 (de) * 2003-07-31 2005-02-24 Grünenthal GmbH Arzneimittel enthaltend Derivate von Aryl( oder Heteroaryl)azolylcarbinolen
ES2244326B1 (es) * 2004-04-05 2007-02-16 Laboratorios Del Dr. Esteve, S.A. Combinacion de substancias activas.
EP1584335A3 (en) * 2004-04-05 2006-02-22 Laboratorios Del Dr. Esteve, S.A. Active substance combination comprising a carbinol composition and an opioid
WO2006010627A1 (en) * 2004-07-30 2006-02-02 Laboratorios Del Dr. Esteve, S.A. Aryl (or heteroaryl) azolylcarbinols
US20060069086A1 (en) * 2004-09-23 2006-03-30 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
US20080045610A1 (en) * 2004-09-23 2008-02-21 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
ES2286920B1 (es) * 2005-02-15 2008-08-16 Laboratorios Del Dr. Esteve, S.A. Derivados de aril (o heteroaril)azolilcarbinoles para el tratamiento de la fibromialgia.
WO2006087147A2 (en) * 2005-02-15 2006-08-24 Laboratorios Del Dr. Esteve, S.A. Derivatives of aryl (or heteroaryl) azolylcarbinols for the treatment of fibromyalgia
EP1695704A1 (en) * 2005-02-28 2006-08-30 Laboratorios Del Dr. Esteve, S.A. Derivatives of aryl (or heteroaryl) azolylcarbinols for the treatment of fibromyalgia
EP1690537A1 (en) * 2005-02-15 2006-08-16 Laboratorios Del Dr. Esteve, S.A. Derivatives of aryl(or heteroaryl) azolycarbinols for the treatment of fibromyalgia
CA2637312A1 (en) * 2006-01-27 2007-08-02 F. Hoffmann-La Roche Ag Use of substituted 2-imidazole of imidazoline derivatives
EP1820502A1 (en) * 2006-02-10 2007-08-22 Laboratorios Del Dr. Esteve, S.A. Active substance combination comprising azolylcarbinol compounds
MX2009003801A (es) 2006-10-19 2009-04-22 Hoffmann La Roche Aminometil-4-imidazoles.
BRPI0718054A2 (pt) 2006-11-02 2013-11-05 Hoffmann La Roche 2-imidazóis substituídos como moduladores de receptores associados à traços de aminas
AU2007321376A1 (en) 2006-11-16 2008-05-22 F. Hoffmann-La Roche Ag Substituted 4-imidazoles
CN101190330A (zh) 2006-11-30 2008-06-04 深圳市鼎兴生物医药技术开发有限公司 胆碱酯酶在拮抗速激肽药物中的应用
WO2008071574A1 (en) 2006-12-13 2008-06-19 F. Hoffmann-La Roche Ag Novel 2 -imidazoles as ligands for trace amine associated receptors (taar)
CA2675221C (en) 2007-02-02 2016-02-23 F. Hoffmann-La Roche Ag Novel 2-aminooxazolines as taar1 ligands
MX2009008465A (es) 2007-02-15 2009-08-20 Hoffmann La Roche Nuevas 2-aminooxazolinas como ligandos de taar1.
CA2691082A1 (en) 2007-07-02 2009-01-08 F. Hoffmann-La Roche Ag 2 -imidazolines having a good affinity to the trace amine associated receptors (taars)
BRPI0812833A2 (pt) 2007-07-03 2014-12-09 Hoffmann La Roche 4-imidazolinas e seu uso como antidepressivos
KR101133862B1 (ko) 2007-07-27 2012-04-06 에프. 호프만-라 로슈 아게 Taar 리간드로서의 2-아제티딘메테인아민 및 2-피롤리딘메테인아민
CA2695331A1 (en) 2007-08-03 2009-02-12 F. Hoffmann-La Roche Ag Pyridinecarboxamide and benzamide derivatives as taar1 ligands
US8242153B2 (en) 2008-07-24 2012-08-14 Hoffmann-La Roche Inc. 4,5-dihydro-oxazol-2YL derivatives
WO2010123999A2 (en) * 2009-04-21 2010-10-28 Auspex Pharmaceuticals, Inc. 1-methylpyrazole modulators of substance p, calcitonin gene-related peptide, adrenergic receptor, and/or 5-ht receptor
US8354441B2 (en) 2009-11-11 2013-01-15 Hoffmann-La Roche Inc. Oxazoline derivatives
US9452980B2 (en) 2009-12-22 2016-09-27 Hoffmann-La Roche Inc. Substituted benzamides
RS60825B1 (sr) 2016-03-17 2020-10-30 Hoffmann La Roche Aktivnost derivata 5-etiol-4-metil-pirazol-3-karboksamida kao agonista taar-a

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5017596A (en) * 1987-04-10 1991-05-21 Laboratorios Del Dr. Esteve, S.A. Arylpyrazolylcarbinol compounds with analgesic activity
WO1997020817A1 (fr) * 1995-12-06 1997-06-12 Laboratorios Del Dr. Esteve, S.A. Procede de separation de carbinols

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2681322B1 (fr) * 1991-09-12 1993-12-17 Laboratorios Dr Esteve Sa Derives d'aryl-heteroaryl-{n-[2-(3,4-dimethoxyphenyl)-ethyl]-n-methyl-3-aminopropoxy}-methane leur preparation et leur application en tant que medicaments .
CA2154116A1 (en) * 1994-07-22 1996-01-23 Philip Arthur Hipskind 1-aryl-2-acetamidopentanone derivatives for use as tachykinin receptor antagonists
ES2234039T3 (es) * 1996-12-02 2005-06-16 MERCK SHARP & DOHME LTD. Uso de antagonistas del receptor nk-1 para tratar trastornos de depresion mayor.
CA2273785A1 (en) * 1996-12-02 1998-06-11 Raymond Baker Use of nk-1 receptor antagonists for treating severe anxiety disorders
EP0942735A1 (en) * 1996-12-02 1999-09-22 MERCK SHARP & DOHME LTD. Use of nk-1 receptor antagonists for treating schizophrenic disorders
WO1998024447A1 (en) * 1996-12-02 1998-06-11 Merck Sharp & Dohme Limited Use of nk-1 receptor antagonists for treating cognitive disorders
ES2150353B1 (es) * 1998-04-15 2001-07-01 Esteve Labor Dr Tienilazolilalcoxietanaminas, su preparacion y su aplicacion como medicamentos.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5017596A (en) * 1987-04-10 1991-05-21 Laboratorios Del Dr. Esteve, S.A. Arylpyrazolylcarbinol compounds with analgesic activity
WO1997020817A1 (fr) * 1995-12-06 1997-06-12 Laboratorios Del Dr. Esteve, S.A. Procede de separation de carbinols

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Беликов В.Г. Фармацевтическая химия. - М.: Высшая школа, 1993, т.1, с.43-47. *

Also Published As

Publication number Publication date
AU5422999A (en) 2000-02-28
HUP0105428A3 (en) 2003-01-28
CZ292065B6 (cs) 2003-07-16
CO5080747A1 (es) 2001-09-25
ES2150378B1 (es) 2001-07-01
NZ509645A (en) 2003-01-31
IL141295A0 (en) 2002-12-01
WO2000007542A2 (es) 2000-02-17
TR200100378T2 (tr) 2001-06-21
DE69914085T2 (de) 2004-11-25
ES2213380T3 (es) 2004-08-16
ES2150378A1 (es) 2000-11-16
DE69914085T8 (de) 2005-04-21
ATE257379T1 (de) 2004-01-15
BR9912807A (pt) 2001-10-16
NO20010634D0 (no) 2001-02-06
AU754124B2 (en) 2002-11-07
PL193802B1 (pl) 2007-03-30
EP1103243B1 (en) 2004-01-07
CN1151789C (zh) 2004-06-02
KR20010079616A (ko) 2001-08-22
TW445259B (en) 2001-07-11
PL346221A1 (en) 2002-01-28
US6518295B1 (en) 2003-02-11
PT1103243E (pt) 2004-05-31
EP1103243A2 (en) 2001-05-30
WO2000007542A3 (es) 2000-05-11
CZ2001412A3 (cs) 2001-08-15
DE69914085D1 (de) 2004-02-12
ZA200100867B (en) 2001-08-16
CA2339661C (en) 2006-10-17
NO20010634L (no) 2001-04-06
CN1317966A (zh) 2001-10-17
JP2002522359A (ja) 2002-07-23
DK1103243T3 (da) 2004-05-03
CA2339661A1 (en) 2000-02-17
AR019999A1 (es) 2002-03-27
KR100558506B1 (ko) 2006-03-07
HUP0105428A2 (hu) 2002-05-29

Similar Documents

Publication Publication Date Title
RU2001106644A (ru) Применение производных арил (или гетероарил) азолилкарбинолов в приготовлении лекарственного средства для лечения нарушений, опосредованных избытком вещества p
JP2002522359A5 (cg-RX-API-DMAC7.html)
JP2002522359A (ja) 過剰のサブスタンスpによって仲介される障害の処置用医薬の製造におけるアリール(またはヘテロアリール)アゾリルカルビノール誘導体の使用
FR2814678A1 (fr) Association d'un antagoniste du recepteur cb1 et de sibutramine, les compositions pharmaceutiques les contenant et leur utilisation pour la traitement de l'obesite
RU2326881C2 (ru) Конденсированные производные азолпиримидина, обладающие свойствами ингибитора фосфатидилинозитол-3-киназы (pi3k)
JP2014521595A5 (cg-RX-API-DMAC7.html)
EA023517B1 (ru) Модуляторы глюкагонового рецептора
JP2007535520A5 (cg-RX-API-DMAC7.html)
SI2855449T1 (en) SULFONYL PIPERIDIN DERIVATIVES AND THEIR USE IN TREATMENT OF PROKINETICINAL DISEASE DISEASES
JP2008517976A5 (cg-RX-API-DMAC7.html)
HUP0004412A2 (hu) Heterociklikus vinil-éterek alkalmazása neurológiai rendellenességek kezelésére szolgáló gyógyszerkészítmények előállítására
CA2484188A1 (en) Tachykinin receptor antagonists
JP2019537603A5 (cg-RX-API-DMAC7.html)
CO6150139A2 (es) Sal de tartrato de 1-[2- fluoruro-4-(trifluorometil)fenil]-3-(3-{[4-metil-5-(4-metil-1,3 oxazol-5-il)-4h-1,2,4-triazol-3 il]tio}propil)-3-azabiciclo[3.1.0]-hexano y a sus solvatos, formulaciones farmaceuticas, procedimientos para su preparacion y su
MXPA06004657A (es) Combinaciones que comprenden un inhibidor de hsp90 y un inhibidor de fosfodiesterasa para tratar o prevenir la neoplasia.
JP2010520917A5 (cg-RX-API-DMAC7.html)
RU2007127864A (ru) Производные n-[(4, 5-дифенил-3-алкил-2-тиенил)метил]амина (амид, сульфонамид, карбамат и карбамид) в качестве антагонистов рецепторов св1 каннабиноидов
CA2313049A1 (en) Cyclooxygenase-2 inhibition
JP2012505226A5 (cg-RX-API-DMAC7.html)
AU2015365954A1 (en) Use of sigma receptor ligands in osteoarthritis
WO2001094369A3 (en) Heterocycle derivatives and methods of use for treating anthrax infection
RU2010153779A (ru) 3- или 4-замещенные пиперидиновые соединения
TNSN06313A1 (fr) Derive de pyrazole cristallin
MXPA01001438A (en) Utilization of aryl(or heteroaryl)azolylcarbinol derivatives in the preparation of a medicament for the treatment of troubles mediated by an excess of substance p
JP2017501193A5 (cg-RX-API-DMAC7.html)

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20070806